A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT04538742. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)
Study identification
- NCT ID
- NCT04538742
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 245 participants
Conditions and interventions
Conditions
Interventions
- Durvalumab Drug
- Paclitaxel Drug
- Pertuzumab Drug
- Trastuzumab deruxtecan Drug
- Tucatinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 27, 2020
- Primary completion
- Jan 30, 2025
- Completion
- Jan 30, 2030
- Last update posted
- Dec 7, 2025
2020 – 2030
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Fort Myers | Florida | 33901 | — |
| Research Site | St. Petersburg | Florida | 33705 | — |
| Research Site | Commack | New York | 11725 | — |
| Research Site | Harrison | New York | 10604 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Columbus | Ohio | 43219 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Fort Worth | Texas | 76104 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04538742, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 7, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04538742 live on ClinicalTrials.gov.